Tokyo based TMS has a lead program that aims to be the first new medicine for acute ischemic stroke in decades

blonca9
Nov 13, 2024
1 min read

CEO Takuro Wakabayashi describes the unmet need in stroke and how this asset found its way into to a partnership with RTW-based Corxel. Plus, further pipeline programs covering hypertension, kidney injury, and spinal cord injury.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Tokyo based TMS has a lead program that aims to be the first new medicine for acute ischemic stroke in decades

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight